Production (Stage)
Axsome Therapeutics, Inc.
AXSM
$103.96
-$1.11-1.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.11% | -20.05% | -54.07% | -67.28% | -86.73% |
| Total Depreciation and Amortization | 17.95% | 16.45% | 12.36% | 8.69% | 21.75% |
| Total Amortization of Deferred Charges | 3.03% | 2.56% | -3.24% | 2.09% | 41.49% |
| Total Other Non-Cash Items | -0.97% | 1.03% | 119.90% | 103.79% | 157.43% |
| Change in Net Operating Assets | 219.50% | 219.40% | 262.22% | 127.68% | -270.68% |
| Cash from Operations | 38.61% | 11.49% | 6.83% | -50.22% | -114.91% |
| Capital Expenditure | 16.26% | 53.61% | 67.33% | -17.07% | -8.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 16.26% | 53.61% | 67.33% | -17.07% | 98.86% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -70.00% |
| Total Debt Repaid | -653.37% | -- | -- | -- | -- |
| Issuance of Common Stock | -61.34% | -73.65% | -79.83% | -85.72% | 24.67% |
| Repurchase of Common Stock | -157.93% | -115.37% | -115.31% | -120.50% | -97.40% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 57.56% | 62.77% | 70.53% | 64.18% | -73.26% |
| Cash from Financing | -68.27% | -82.53% | -86.87% | -90.21% | -8.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -135.95% | -138.22% | -147.20% | -133.39% | -47.51% |